Ad
Search
Generic filters
Filter by content type
Taxonomy terms

VBLT – Vascular Biogenics Ltd

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

3

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 5

Low: 5

High: 5

Total Analysts: 4

Company Profile

Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses